Temporal Trend and Clinical Outcomes in HIV and Non-HIV Patients following Liposuction: A Propensity-Matched Analysis.
Journal
Plastic and reconstructive surgery
ISSN: 1529-4242
Titre abrégé: Plast Reconstr Surg
Pays: United States
ID NLM: 1306050
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
pubmed:
8
10
2022
medline:
31
12
2022
entrez:
7
10
2022
Statut:
ppublish
Résumé
Because of the availability of highly active antiretroviral therapy, individuals infected with human immunodeficiency virus (HIV) are enjoying greater longevity with chronic conditions including abnormal adipose distribution. However, prior data on postoperative outcomes of liposuction in HIV-positive patients were limited by small sample size. Therefore, the authors aimed to compare differences in temporary trend, clinical characteristics, and outcomes between patients with and without HIV who underwent liposuction. The National Inpatient Sample database from 2010 to 2017 was queried to identify patients who underwent liposuction. Univariate, multivariate logistic regression and 1:4 propensity score-matched analyses were used to assess the primary outcomes (i.e., in-hospital mortality and postoperative outcomes) and secondary outcomes (i.e., discharge disposition, prolonged length of stay, and total cost). Overall, 19,936 patients who underwent liposuction were identified, among whom 61 patients (0.31%) were infected with HIV. Patients with HIV were more likely to be male, insured by Medicare, and had more comorbidities and lower income. Unadjusted length of stay was longer among patients with HIV (OR, 1.81; 95% CI, 1.09 to 2.99; P = 0.020); nevertheless, multivariable models and propensity score-matched analysis demonstrated that patients with HIV were no more likely to have complications than the general population. This was also the case for length of stay and total costs. The authors' findings indicated that patients with HIV who underwent liposuction did not experience an increased risk of major complication or mortality. Liposuction could be safely considered as a surgical treatment for HIV-positive patients with local fat deposition. Risk, II.
Sections du résumé
BACKGROUND
Because of the availability of highly active antiretroviral therapy, individuals infected with human immunodeficiency virus (HIV) are enjoying greater longevity with chronic conditions including abnormal adipose distribution. However, prior data on postoperative outcomes of liposuction in HIV-positive patients were limited by small sample size. Therefore, the authors aimed to compare differences in temporary trend, clinical characteristics, and outcomes between patients with and without HIV who underwent liposuction.
METHODS
The National Inpatient Sample database from 2010 to 2017 was queried to identify patients who underwent liposuction. Univariate, multivariate logistic regression and 1:4 propensity score-matched analyses were used to assess the primary outcomes (i.e., in-hospital mortality and postoperative outcomes) and secondary outcomes (i.e., discharge disposition, prolonged length of stay, and total cost).
RESULTS
Overall, 19,936 patients who underwent liposuction were identified, among whom 61 patients (0.31%) were infected with HIV. Patients with HIV were more likely to be male, insured by Medicare, and had more comorbidities and lower income. Unadjusted length of stay was longer among patients with HIV (OR, 1.81; 95% CI, 1.09 to 2.99; P = 0.020); nevertheless, multivariable models and propensity score-matched analysis demonstrated that patients with HIV were no more likely to have complications than the general population. This was also the case for length of stay and total costs.
CONCLUSIONS
The authors' findings indicated that patients with HIV who underwent liposuction did not experience an increased risk of major complication or mortality. Liposuction could be safely considered as a surgical treatment for HIV-positive patients with local fat deposition.
CLINICAL QUESTION/LEVEL OF EVIDENCE
Risk, II.
Identifiants
pubmed: 36205655
doi: 10.1097/PRS.0000000000009795
pii: 00006534-202301000-00014
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47e-55eInformations de copyright
Copyright © 2022 by the American Society of Plastic Surgeons.
Déclaration de conflit d'intérêts
Disclosure : None of the authors have any commercial associations or financial disclosures that might pose or create a conflict of interest with the methods applied or the results presented in this article .
Références
UNAIDS. UNAIDS report on the global AIDS pandemic 2020. Available at: https://genderandaids.unwomen.org/en/resources/2020/07/unaids-global-report-on-the-global-aids-pandemic-2020 . Accessed July 6, 2020.
Farahani M, Mulinder H, Farahani A, Marlink R. Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis. Int J STD AIDS. 2017;28:636–650.
Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet. 2000;355:1158–1159.
Leow MK, Addy CL, Mantzoros CS. Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab. 2003;88:1961–1976.
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62.
Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293–301.
Sánchez Torres AM, Munoz Muniz R, Madero R, Borque C, García-Miguel MJ, De José Gómez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr. 2005;164:271–276.
Puttawong S, Prasithsirikul W, Vadcharavivad S. Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai. 2004;87:605–611.
Sattler F. Body habitus changes related to lipodystrophy. Clin Infect Dis. 2003;36(Suppl 2):S84–S90.
Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG; HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726–735.
Koethe JR, Lagathu C, Lake JE, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6:48.
Fuller J. A 39-year-old man with HIV-associated lipodystrophy. JAMA. 2008;300:1056–1066.
Vanangamudi M, Kurup S, Namasivayam V. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens. Curr Opin Pharmacol. 2020;54:179–187.
Chastain MA, Chastain JB, Coleman WP. HIV lipodystrophy: review of the syndrome and report of a case treated with liposuction. Dermatol Surg. 2001;27:497–500.
Wolfort FG, Cetrulo CL Jr, Nevarre DR. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast Reconstr Surg. 1999;104:1814–1820; discussion 1821–1822.
Gervasoni C, Ridolfo AL, Vaccarezza M, et al. Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. AIDS. 2004;18:574–576.
Onesti MG, Fioramonti P, Carella S, Spinelli G, Scuderi N. Nd:YAG laser-assisted liposuction for an HIV patient. Aesthetic Plast Surg. 2010;34:528–530.
Piliero PJ, Hubbard M, King J, Faragon JJ. Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad. Clin Infect Dis. 2003;37:1374–1377.
Tadisina KK, Chopra K, Singh DP. The “weekend effect” in plastic surgery: analyzing weekday versus weekend admissions in body contouring procedures from 2000 to 2010. Aesthet Surg J. 2015;35:995–998.
Ogunbayo GO, Ha LD, Ahmad Q, et al. Treatment bias in management of HIV patients admitted for acute myocardial infarction: does it still exist? J Gen Intern Med. 2020;35:57–62.
Vallabhajosyula S, Subramaniam AV, Sundaragiri PR, et al. Influence of human immunodeficiency virus infection on the management and outcomes of acute myocardial infarction with cardiogenic shock. J Acquir Immune Defic Syndr. 2020;85:331–339.
Kirchebner J, Günther MP, Sonnweber M, King A, Lau S. Factors and predictors of length of stay in offenders diagnosed with schizophrenia: a machine-learning-based approach. BMC Psychiatry. 2020;20:201.
Pisarska M, Dworak J, Natkaniec M, et al. Risk factors for prolonged hospitalization in patients undergoing laparoscopic adrenalectomy. Wideochir Inne Tech Maloinwazyjne. 2018;13:141–147.
Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26:734–753.
Winger DG, Nason KS. Propensity-score analysis in thoracic surgery: when, why, and an introduction to how. J Thorac Cardiovasc Surg. 2016;151:1484–1487.
Leung J, Peacock A, Colledge S, et al. A global meta-analysis of the prevalence of HIV, hepatitis C virus, and hepatitis B virus among people who inject drugs: do gender-based differences vary by country-level indicators? J Infect Dis. 2019;220:78–90.
The Lancet . The global HIV/AIDS epidemic-progress and challenges. Lancet. 2017;390:333.
Kermode M, Songput CH, Sono CZ, Jamir TN, Devine A. Meeting the needs of women who use drugs and alcohol in North-east India: a challenge for HIV prevention services. BMC Public Health. 2012;12:825.
West BS, Pouget ER, Tempalski B, et al. Female and male differences in AIDS diagnosis rates among people who inject drugs in large U.S. metro areas from 1993 to 2007. Ann Epidemiol. 2015;25:218–225.
Tabler J, Mykyta L, Nagata JM. The association between HIV/AIDS and food insecurity at the US-Mexico border: experiences of low-income patients in the Rio Grande Valley. Int J STD AIDS. 2021;32:14–22.
Beyrer C, Sullivan P, Adimora AA, Mayer K. HIV in the USA: priorities for the new administration. Lancet. 2020;396:1862–1863.
Robich MP, Schiltz N, Johnston DR, et al. Outcomes of patients with human immunodeficiency virus infection undergoing cardiovascular surgery in the United States. J Thorac Cardiovasc Surg. 2014;148:3066–3073.
Donnally CJ III, Kalakoti P, Buskard ANL, et al. Inpatient outcomes after elective lumbar spinal fusion for patients with human immunodeficiency virus in the absence of acquired immunodeficiency syndrome. World Neurosurg. 2018;116:e913–e920.
Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300:550–554.
Degenhardt L, Charlson F, Stanaway J, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16:1385–1398.
Mathers BM, Degenhardt L, Phillips B, et al.; 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–1745.
Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138:1100–1112.
Crum-Cianflone NF, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: authors’ reply. AIDS. 2009;23:1791–1792.
So-Armah K, Benjamin LA, Bloomfield GS, et al. HIV and cardiovascular disease. Lancet HIV. 2020;7:e279–e293.
Tackling cancer and heart disease in people with HIV/AIDS. Lancet. 2011;377:1380.
Iverson RE, Lynch DJ; American Society of Plastic Surgeons Committee on Patient Safety. Practice advisory on liposuction. Plast Reconstr Surg. 2004;113:1478–1490; discussion 1491–1495.
French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4:16–21.
Ponce-de-Leon S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodystrophy. Lancet. 1999;353:1244.
Davison SP, Timpone J Jr, Hannan CM. Surgical algorithm for management of HIV lipodystrophy. Plast Reconstr Surg. 2007;120:1843–1858.
Hultman CS, McPhail LE, Donaldson JH, Wohl DA. Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy. Ann Plast Surg. 2007;58:255–263.